Related Experiment Video
Updated: May 17, 2026
In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
Published on: August 20, 2016
[Effects of matrix metalloproteinases inhibitor GM6001 on choroidal neovascularization]
1Department of Ophthalmology, People's Liberation Army General Hospital, Beijing, China.
Objective:
To explore the efficiency of GM6001 for the inhibition of choroidal neovascularization.
Methods:
Experimental study. Twenty-four Brown Norvy (BN) rats after photocoagulation were randomly divided into 3 groups as GM6001 group, DMSO group and CONT group. GM6001 (0.2 ml of 0.1% suspension) was injected retrobulbar for GM6001 group and 0.2 ml DMSO was injected for DMSO group on days 1, 3, 6, 9, and 12 after photocoagulation. No injection was performed in the CONT group. Fundus fluorescence angiography, histopathology, immunohistochemistry and quantitative analysis of choroidal neovascularization (CNV) were performed 3 weeks after photocoagulation. One-way ANOVA was used in conjunction with SNK-t test to assess statistical significance within groups.
Results:
The fluorescein leakage appeared in all three groups; but fluorescein leakage of GM6001 group (74.56 ± 2.33) was less than that of DMSO group (119.57 ± 1.15)and CONT group (122.36 ± 2.38) (F = 403.23, P = 0.001; LSD-t test, all P value < 0.01), whereas fluorescein leakage of DMSO group was similar to that in the CONT group. The retinal and choroidal capillaries in the CONT group were damaged and disordered; a great deal of CNV and migration and proliferation of retinal pigment epithelium cells, fibrocytes and collagen fibers were discovered. Pathological changes in DMSO group were similar to those in the CONT group. There were a small quantity of retinal pigment epithelium cells, fibrocytes and CNV in GM6001 group. Although the immunohistochemical staining for CD105 displayed positive results in all three groups, positive staining of GM6001 group (19.85 ± 1.59) was significantly less than that of the CONT group (38.02 ± 2.57) and DMSO group (39.02 ± 3.12) (F = 55.57, P = 0.001; LSD-t test, all P value < 0.01). Positive staining of CD105 in the CONT group was similar to that of DMSO group (P > 0.05). The size of CNV in GM6001 group (15.35 ± 0.77) was significantly less than that of CONT group (28.38 ± 1.60) and DMSO group (28.74 ± 1.19) (F = 114.85, P = 0.001; LSD-t test, all P value < 0.01). There was no statistical difference for the size of CNV between CONT group and DMSO group (P > 0.05).
Conclusion:
GM6001 effectively inhibits CVS induced by krypton laser photocoagulation.
Insights
GM6001 effectively inhibits choroidal neovascularization (CNV) by reducing fluorescein leakage and the size of CNV lesions. This study demonstrates GM6001
Area of Science:
- Ophthalmology
- Vascular Biology
- Pharmacology
Context:
- Choroidal neovascularization (CNV) is a major cause of vision loss.
- Current treatments for CNV have limitations.
- GM6001 is a potential therapeutic agent for CNV.
Purpose:
- To evaluate the efficacy of GM6001 in inhibiting CNV.
- To assess the impact of GM6001 on CNV-related biomarkers.
Summary:
- GM6001 significantly reduced fluorescein leakage and CNV size in a rat model.
- Histopathology and immunohistochemistry confirmed reduced CNV and CD105 expression in the GM6001 group.
- GM6001 demonstrated superior efficacy compared to DMSO and control groups.
Impact:
- GM6001 shows promise as a novel therapeutic for inhibiting CNV.
- Further research may explore GM6001's clinical applications in treating neovascular eye diseases.
- This study provides a basis for developing new anti-angiogenic therapies.
